FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891302184> ?p ?o ?g. }

• W2891302184 endingPage "566" @default.
• W2891302184 startingPage "560" @default.
• W2891302184 abstract "We aim to assess the effect of phosphodiesterase type 5 inhibitors (PDE5I) on prostate cancer risk as well on biochemical recurrence after radical prostatectomy. We performed a research using the following keywords “Phosphodiesterase type 5 inhibitors” and “Prostate cancer”. Only trials examining the effect of PDE5I on prostate cancer risk and recurrence after radical prostatectomy were included. Seventeen preclinical trials and seven clinical trials were included. Preclinical studies demonstrate a pivotal role for PDE5I as a modulator of apoptosis preventing prostate carcinogenesis. The clinical benefit of PDE5I was not demonstrated. PDE5I use was not associated with decreased prostate cancer diagnosis in two retrospective cohort studies. Biochemical recurrence after radical prostatectomy was not lower (nor higher) in patients taking PDE5I in three retrospective case match studies. Based on this review, a change in our practice regarding pharmacological reeducation after radical prostatectomy is not justified. Le but de cette revue est de revoir l’implication éventuelle des inhibiteurs de phosphodiestérase de type 5 (IPDE5) dans la genèse et la progression du cancer de la prostate. Une recherche a été menée, en décembre 2017, sur la base des données usuelles en utilisant les mots-clés suivant : « Phosphodiesterase type 5 inhibitors » et « Prostate cancer ». Seuls les essais précliniques et cliniques examinant une association entre la prise des IPDE5 et la genèse et/ou la progression du cancer de la prostate étaient inclus. Dix-sept études précliniques et sept études cliniques ont été retenues. Les études cliniques plaident en faveur d’un effet protecteur des IPDE5 contre le cancer de la prostate. Le bénéfice clinique de cette association est contradictoire. La synthèse des données montre l’absence d’un risque accru de récidive biologique chez les utilisateurs. Il n’y a pas non plus une association entre la prise des IPDE5 et le risque de développer un cancer de la prostate. En se basant sur cette revue, une modification de notre pratique concernant la rééducation pharmacologique après prostatectomie totale n’est pas justifiée. Il n’y a pas non plus d’évidence à utiliser ce genre de traitement en prévention primaire ou secondaire dans le cancer de la prostate." @default.
• W2891302184 created "2018-09-27" @default.
• W2891302184 creator A5001181706 @default.
• W2891302184 creator A5001474630 @default.
• W2891302184 creator A5011394571 @default.
• W2891302184 creator A5016189522 @default.
• W2891302184 creator A5016810722 @default.
• W2891302184 creator A5037175939 @default.
• W2891302184 creator A5057962494 @default.
• W2891302184 creator A5066738891 @default.
• W2891302184 creator A5072948757 @default.
• W2891302184 date "2018-10-01" @default.
• W2891302184 modified "2023-10-13" @default.
• W2891302184 title "Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review" @default.
• W2891302184 cites W1972432830 @default.
• W2891302184 cites W1994262926 @default.
• W2891302184 cites W2005611867 @default.
• W2891302184 cites W2007454357 @default.
• W2891302184 cites W2015455553 @default.
• W2891302184 cites W2029622281 @default.
• W2891302184 cites W2089336390 @default.
• W2891302184 cites W2091019294 @default.
• W2891302184 cites W2093604820 @default.
• W2891302184 cites W2103380911 @default.
• W2891302184 cites W2109543271 @default.
• W2891302184 cites W2114021843 @default.
• W2891302184 cites W2116652282 @default.
• W2891302184 cites W2118756223 @default.
• W2891302184 cites W2120539661 @default.
• W2891302184 cites W2121758806 @default.
• W2891302184 cites W2130815390 @default.
• W2891302184 cites W2134833483 @default.
• W2891302184 cites W2138365326 @default.
• W2891302184 cites W2142353362 @default.
• W2891302184 cites W2148636633 @default.
• W2891302184 cites W2151554163 @default.
• W2891302184 cites W2152502176 @default.
• W2891302184 cites W2206444050 @default.
• W2891302184 cites W2219868133 @default.
• W2891302184 cites W2281105310 @default.
• W2891302184 cites W2321119817 @default.
• W2891302184 cites W2327698743 @default.
• W2891302184 cites W2347522117 @default.
• W2891302184 cites W2730880462 @default.
• W2891302184 cites W2807400090 @default.
• W2891302184 cites W4247903468 @default.
• W2891302184 doi "https://doi.org/10.1016/j.purol.2018.07.004" @default.
• W2891302184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30201551" @default.
• W2891302184 hasPublicationYear "2018" @default.
• W2891302184 type Work @default.
• W2891302184 sameAs 2891302184 @default.
• W2891302184 citedByCount "4" @default.
• W2891302184 countsByYear W28913021842019 @default.
• W2891302184 countsByYear W28913021842021 @default.
• W2891302184 countsByYear W28913021842022 @default.
• W2891302184 countsByYear W28913021842023 @default.
• W2891302184 crossrefType "journal-article" @default.
• W2891302184 hasAuthorship W2891302184A5001181706 @default.
• W2891302184 hasAuthorship W2891302184A5001474630 @default.
• W2891302184 hasAuthorship W2891302184A5011394571 @default.
• W2891302184 hasAuthorship W2891302184A5016189522 @default.
• W2891302184 hasAuthorship W2891302184A5016810722 @default.
• W2891302184 hasAuthorship W2891302184A5037175939 @default.
• W2891302184 hasAuthorship W2891302184A5057962494 @default.
• W2891302184 hasAuthorship W2891302184A5066738891 @default.
• W2891302184 hasAuthorship W2891302184A5072948757 @default.
• W2891302184 hasConcept C121608353 @default.
• W2891302184 hasConcept C126322002 @default.
• W2891302184 hasConcept C143998085 @default.
• W2891302184 hasConcept C2777008409 @default.
• W2891302184 hasConcept C2779466945 @default.
• W2891302184 hasConcept C2779929075 @default.
• W2891302184 hasConcept C2780192828 @default.
• W2891302184 hasConcept C29456083 @default.
• W2891302184 hasConcept C71924100 @default.
• W2891302184 hasConcept C74534348 @default.
• W2891302184 hasConceptScore W2891302184C121608353 @default.
• W2891302184 hasConceptScore W2891302184C126322002 @default.
• W2891302184 hasConceptScore W2891302184C143998085 @default.
• W2891302184 hasConceptScore W2891302184C2777008409 @default.
• W2891302184 hasConceptScore W2891302184C2779466945 @default.
• W2891302184 hasConceptScore W2891302184C2779929075 @default.
• W2891302184 hasConceptScore W2891302184C2780192828 @default.
• W2891302184 hasConceptScore W2891302184C29456083 @default.
• W2891302184 hasConceptScore W2891302184C71924100 @default.
• W2891302184 hasConceptScore W2891302184C74534348 @default.
• W2891302184 hasIssue "12" @default.
• W2891302184 hasLocation W28913021841 @default.
• W2891302184 hasLocation W28913021842 @default.
• W2891302184 hasOpenAccess W2891302184 @default.
• W2891302184 hasPrimaryLocation W28913021841 @default.
• W2891302184 hasRelatedWork W1506464168 @default.
• W2891302184 hasRelatedWork W1995051622 @default.
• W2891302184 hasRelatedWork W2009319121 @default.
• W2891302184 hasRelatedWork W2021957287 @default.
• W2891302184 hasRelatedWork W2084343070 @default.
• W2891302184 hasRelatedWork W2129602766 @default.
• W2891302184 hasRelatedWork W2412226549 @default.

• next